Immuneering (IMRX)
NASDAQ:IMRX
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 316.95K | $ 2.08M |
| Gross Profit | $ -698.89K | $ 0.00 | $ 0.00 | $ 158.83K | $ 926.89K |
| Operating Income | $ -59.38M | $ -64.07M | $ -58.41M | $ -51.74M | $ -33.89M |
| EBITDA | $ -58.68M | $ -63.69M | $ -58.06M | $ -51.47M | $ -33.73M |
| Net Income | $ -56.02M | $ -61.04M | $ -53.47M | $ -50.51M | $ -33.54M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 172.83M | $ 36.14M | $ 85.67M | $ 105.52M | $ 149.20M |
| Total Assets | $ 231.99M | $ 52.71M | $ 102.58M | $ 122.37M | $ 166.70M |
| Total Debt | $ 3.82M | $ 4.16M | $ 4.46M | $ 4.84M | $ 5.36M |
| Net Debt | $ -124.82M | $ -31.98M | $ -54.94M | $ -67.80M | $ -69.52M |
| Total Liabilities | $ 13.50M | $ 11.33M | $ 12.01M | $ 12.52M | $ 10.72M |
| Stockholders' Equity | $ 218.48M | $ 41.39M | $ 90.58M | $ 109.85M | $ 155.98M |
| Cash Flow | |||||
| Free Cash Flow | $ -45.49M | $ -55.08M | $ -49.31M | $ -44.84M | $ -30.91M |
| Operating Cash Flow | $ -45.34M | $ -55.00M | $ -48.97M | $ -44.10M | $ -30.85M |
| Investing Cash Flow | $ -88.74M | $ 26.43M | $ 7.30M | $ 41.83M | $ -75.62M |
| Financing Cash Flow | $ 226.58M | $ 5.30M | $ 28.44M | $ 19.00K | $ 144.26M |